≡ Risteys
FG R12 + FR

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

See these related core endpoints for full statistics:

Use of peginterferon beta-1a

Endpoint Browser

MSMED_PEGINTERFERONBETA1A

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

520210

1. Apply sex-specific rule

None

520210

2. Check conditions

None

520210

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Medicine purchases: ATC — L03AB13

1 out of 7 registries used, show all original rules.

134

4. Check minimum number of events

Min. number of events 3
134

5. Include endpoints

None

134

6. Filter based on genotype QC (FinnGen only)

134

Control definitions (FinnGen only)

Controls for this endpoint are individuals that are not cases.

Extra metadata

First used in FinnGen datafreeze
DF2

Case counts by codes

↥

FinnGen case counts by registry codes:

Not enough data for upset plot.

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 134 113 21
Unadjusted period prevalence (%) 0.03 0.04 0.01
Median age at first event (years) 40.36 38.46 50.58

-FinnGen-

Age distribution of first events

0102030405060051015202530354045AgeIndividuals

-FinnGen-

Year distribution of first events

1970197519801985199019952000200520102015202020230102030405060708090YearIndividuals

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
111
Matched controls
1108
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L03AB13
ATC
peginterferon beta-1a; parenteral
+∞
160.1
111
*
109
Kela drug reimbursment
Multiple sclerosis
+∞
151.9
111
5
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
+∞
151.9
111
5
G35
ICD-10 Finland
Multiple sclerosis
+∞
150.6
111
6
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
2924.0
131.6
102
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
42.0
55.9
74
50
L03AB07
ATC
interferon beta-1a; parenteral
431.4
53.0
49
*
TAB00
NOMESCO Finland
Lumbar puncture
37.7
43.8
57
30
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
106.3
43.1
45
7
H46
ICD-10 Finland
Optic neuritis
118.4
37.8
39
5
L04AA31
ATC
teriflunomide; oral
221.9
32.6
32
*
N86
ICPC
Multiple sclerosis
176.3
26.9
27
*
L03AX13
ATC
glatiramer acetate; parenteral
+∞
26.1
24
*
N07XX09
ATC
[U] dimethyl fumarate; oral
302.6
24.7
24
*
L04AX07
ATC
dimethyl fumarate; oral
143.5
22.5
23
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
12.4
20.9
40
48
164
Kela drug reimbursment
Fingolimod
+∞
20.4
19
*
N04BB01
ATC
amantadine; oral
128.1
20.3
21
*
L03AB08
ATC
interferon beta-1b; parenteral
241.3
20.3
20
*
XA800
NOMESCO Finland
Neuropsychological investigation
23.8
18.4
26
14
353
Kela drug reimbursment
Cladribine and fingolimod
+∞
17.1
16
*
2AB04
NOMESCO Finland
NA
57.2
13.2
15
*
NA1CG
NOMESCO Finland
Cervical spine extensive MRI examination with high intensity magnet
42.9
12.6
15
*
R20.2
ICD-10 Finland
Paraesthesia of skin
7.8
12.5
30
50
L04AA27
ATC
fingolimod; oral
+∞
11.7
11
*
XCK00
NOMESCO Finland
Perimetry
13.3
11.6
20
18
XKD06
NOMESCO Finland
Physiologic investigation of micturition
24.4
11.0
15
7
G04BD12
ATC
mirabegron; oral
10.8
10.6
20
22
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
11.2
10.3
19
20
XKC03
NOMESCO Finland
Water cystometry
60.4
9.8
11
*
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
14.1
9.7
16
13
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
19.8
9.7
14
8
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
9.1
9.7
20
26
C10AC01
ATC
colestyramine; oral
33.3
9.6
12
*
XKD03
NOMESCO Finland
Urethral pressure profilometry
54.4
8.8
10
*
XKD00
NOMESCO Finland
Uroflowmetry
9.3
8.5
17
21
G36.9
ICD-10 Finland
Acute disseminated demyelination, unspecified
+∞
8.4
8
*
KCV12
NOMESCO Finland
Urinary bladder endoscopic botulin therapy
+∞
8.4
8
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
6.9
8.2
20
34
NA2CG
NOMESCO Finland
Thoracal spine extensive MRI examination with high intensity magnet
48.5
7.8
9
*
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
48.5
7.8
9
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
4.2
7.7
31
93
G04BD09
ATC
trospium; oral
27.2
7.7
10
*
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
8.5
7.2
15
20
NA2BG
NOMESCO Finland
Thoracal spine MRI examination with high intensity magnet
12.1
7.0
12
11
ZX120
NOMESCO Finland
Intravenous
6.3
7.0
18
33
TKC22
NOMESCO Finland
Catheterisation instruction
42.7
6.8
8
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
5.4
6.8
20
43
G04BD07
ATC
tolterodine; oral
28.5
6.3
8
*
N31.9
ICD-10 Finland
Neuromuscular dysfunction of bladder, unspecified
+∞
6.3
6
*
UKC02
NOMESCO Finland
Cystoscopy
5.7
6.2
17
34
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
16.1
6.0
9
6

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
37
22
22.85
46.23
1.1
1.3
—
—
—
0
0
39
26
20.75
46.17
1.3
1.2
—
—
—
0
0
34
26
17.18
37.12
1.0
1.2
13.68
2.95
e6/l
1.82
28
19
34
26
17.18
37.12
1.0
1.2
88.96
47.24
e6/l
0.23
28
21
127
548
26.18
36.60
9.9
5.1
0.50
0.52
e9/l
0.81
118
486
105
336
10.82
36.47
8.7
4.9
—
—
—
0
0
127
551
25.94
36.35
9.9
5.1
0.03
0.04
e9/l
2.27
118
487
38
7
74.84
34.44
1.1
1.1
185.75
254.43
mg/l
—
32
7
127
576
24.03
34.09
10.0
5.0
1.66
2.23
e9/l
2.10
118
521
127
576
24.03
34.09
10.0
5.8
0.18
0.18
e9/l
0.01
118
525
31
27
14.64
31.18
1.0
1.3
3.27
3.52
mmol/l
1.61
26
27
33
7
61.84
29.02
1.2
1.1
—
—
—
0
0
124
628
14.06
22.79
10.5
7.9
2.98
3.93
e9/l
7.67
116
551
18
13
15.84
19.73
1.1
1.1
—
—
—
0
0
12
11
11.88
11.22
1.1
1.3
—
—
—
0
0
15
7
23.89
10.95
1.6
2.3
78.67
81.86
%
—
15
7
36
116
3.88
9.98
1.4
1.4
—
—
—
0
0
87
496
3.15
9.27
11.1
6.6
0.00
0.00
e9/l
0.50
77
400
53
236
3.06
8.67
6.2
6.3
—
—
—
0
0
109
726
3.69
8.59
5.9
4.0
—
1900.86
—
0
7
114
784
4.04
8.48
5.8
3.7
—
—
—
0
0
11
5
23.76
8.16
3.3
1.0
0.13
0.35
e9/l
—
11
5
66
345
2.80
7.88
2.6
4.5
38.62
37.56
g/l
1.02
56
325
16
32
5.54
7.88
1.3
1.3
—
—
—
0
0
49
223
2.89
7.55
3.8
2.4
0.15
0.16
e6/l
0.03
41
160
53
255
2.78
7.32
3.6
2.6
7.63
67.48
e6/l
1.57
45
187
129
1064
6.69
7.00
5.8
4.7
1.63
1.68
mu/l
0.25
129
1010
25
79
3.66
6.99
1.6
1.2
—
—
—
0
0
49
236
2.70
6.66
3.7
2.5
—
—
—
0
0
134
1190
+∞
6.27
17.7
7.6
25.56
24.19
u/l
0.61
134
1153
43
202
2.66
6.07
1.4
1.5
—
—
—
0
0
60
338
2.40
5.71
5.2
3.2
3.44
62.41
e6/l
1.94
47
205
29
126
2.66
4.68
3.7
2.2
1.46
4.86
e6/l
1.94
13
63
7
6
12.21
4.32
1.3
2.3
26.86
28.00
%
—
7
6
7
6
12.21
4.32
1.1
1.0
1478.57
1572.67
miu/ml
—
7
6
50
307
2.00
3.51
1.6
1.7
88.14
93.18
pmol/l
0.48
30
166
63
425
1.91
3.32
3.7
2.8
—
—
—
0
0
9
21
4.51
3.05
1.6
3.8
2.60
3.59
e9/l
—
9
21
9
21
4.51
3.05
1.6
3.9
54.00
55.19
%
—
9
21
27
138
2.20
3.02
2.3
2.4
4377.56
3036.92
u/l
—
9
61
46
296
1.84
2.70
5.7
4.1
—
—
—
0
0
44
281
1.84
2.64
2.8
2.2
—
—
—
0
0
8
20
4.18
2.61
1.4
1.7
—
—
—
0
0
72
541
1.72
2.43
6.8
4.4
0.00
0.00
estimate
0.00
15
117
72
542
1.71
2.40
4.3
3.0
0.00
0.00
estimate
0.00
15
112
56
396
1.71
2.33
1.8
1.8
—
—
—
0
0
0
63
0.00
2.27
0.0
1.2
—
—
—
0
0
12
48
2.65
2.25
1.2
2.2
58.80
72.64
e9/l
—
7
37
72
550
1.67
2.22
4.3
3.2
0.00
0.00
estimate
0.00
15
112
39
253
1.76
2.18
6.3
6.5
1.26
1.05
inr
0.59
12
89
65
487
1.65
2.13
1.7
2.1
—
—
—
0
0
125
1143
2.39
2.06
8.5
9.7
14.01
19.67
mg/l
1.52
83
859
71
551
1.61
1.98
2.7
4.8
5.68
6.34
mmol/l
4.06
63
479
6
16
3.87
1.95
1.2
1.1
—
—
—
0
0
9
34
2.76
1.90
1.9
1.9
—
—
—
0
0
8
30
2.77
1.75
2.7
2.1
—
—
—
0
0
134
1294
+∞
1.74
24.6
14.5
89.69
89.92
fl
0.27
134
1279
134
1294
+∞
1.74
24.5
14.5
29.91
30.04
pg
0.44
134
1278
115
1027
1.84
1.69
19.7
11.7
13.37
13.44
%
0.28
115
1014
9
183
0.46
1.67
1.4
1.3
—
—
—
0
0
6
20
3.09
1.60
1.0
1.0
—
—
—
0
0
8
33
2.51
1.56
2.5
3.9
139.88
134.24
g/l
—
8
33
134
1295
+∞
1.53
24.6
14.7
134.44
134.58
g/l
0.05
134
1279
34
233
1.62
1.52
4.8
3.2
—
—
—
0
0
36
251
1.59
1.50
1.5
1.9
2.54
2.96
mg/l
0.61
29
218
99
1096
0.63
1.46
2.9
3.4
2.95
2.85
mmol/l
0.67
89
1038
98
1087
0.63
1.45
2.9
3.2
1.39
1.52
mmol/l
2.72
90
1031
99
1095
0.63
1.44
2.8
3.2
4.74
4.75
mmol/l
0.06
93
1037
38
277
1.52
1.30
1.9
1.3
2.28
2.16
g/l
0.28
31
177
8
38
2.17
1.20
1.5
1.6
—
—
—
0
0
5
20
2.56
1.16
4.6
2.3
—
—
—
0
0
5
20
2.56
1.16
1.0
1.1
—
—
—
0
0
92
807
1.45
1.16
2.5
3.3
8.61
7.90
mm/h
0.34
87
754
95
1044
0.69
1.09
2.6
2.9
1.10
1.18
mmol/l
0.91
87
985
12
194
0.58
0.98
3.9
4.2
15.61
19.05
mg/mmol
—
7
121
48
385
1.38
0.98
3.2
7.6
1.22
1.21
mmol/l
0.15
39
329
7
37
1.94
0.95
3.7
1.9
—
—
—
0
0
15
226
0.62
0.93
1.4
1.5
—
—
—
0
0
6
28
2.19
0.93
1.3
1.3
—
—
—
0
0
6
29
2.12
0.90
2.2
4.0
27.03
23.82
mmol/l
—
6
29
12
189
0.60
0.89
3.8
3.5
6028.11
119.26
mg/l
—
7
125
119
1117
1.58
0.88
17.9
10.5
40.03
40.12
%
0.05
100
936
27
202
1.42
0.81
3.3
2.2
—
—
—
0
0
0
24
0.00
0.80
0.0
1.0
—
1.28
—
0
10
37
455
0.74
0.78
2.0
1.7
—
—
—
0
0
99
906
1.35
0.78
3.9
4.2
14.43
14.39
pmol/l
0.07
91
854
8
132
0.58
0.78
1.3
1.4
—
—
—
0
0
39
471
0.76
0.72
1.9
2.1
—
—
—
0
0
7
41
1.75
0.71
1.0
1.4
—
—
—
0
0
41
336
1.32
0.71
1.6
1.9
—
—
—
0
0
8
126
0.61
0.68
1.0
1.2
—
—
—
0
0
24
183
1.38
0.65
1.7
2.5
25.64
65.58
ug/g
2.47
14
146
5
29
1.75
0.64
2.0
2.1
0.96
1.35
%
—
5
29
5
30
1.69
0.62
2.6
1.2
—
—
—
0
0
22
167
1.38
0.62
1.5
1.4
160.00
472.31
titre
—
6
26
7
114
0.59
0.61
1.7
2.7
—
—
—
0
0
0
21
0.00
0.60
0.0
1.1
—
1.41
—
0
9
32
260
1.30
0.58
1.4
1.7
0.51
0.69
mg/l
0.61
23
188
32
260
1.30
0.58
2.1
2.4
7.53
16.54
ng/l
3.00
15
108
8
54
1.51
0.58
2.6
3.3
—
—
—
0
0
14
100
1.45
0.54
5.5
3.2
—
—
—
0
0
34
286
1.25
0.48
1.6
2.8
2.31
2.34
mmol/l
0.77
27
256
0
16
0.00
0.41
0.0
12.3
—
851.25
—
0
16
0
16
0.00
0.41
0.0
18.1
—
1736.88
—
0
16
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
8
61
1.33
0.40
1.1
1.4
—
—
—
0
0
39
340
1.21
0.40
2.4
6.6
1.21
1.21
mmol/l
0.38
32
317
10
75
1.36
0.31
1.1
1.1
—
—
—
0
0
18
149
1.24
0.29
2.2
2.8
30.78
258.96
ng/l
—
9
70
9
117
0.75
0.29
1.4
1.5
—
—
—
0
0
10
128
0.76
0.28
1.7
2.9
0.87
0.83
mmol/l
—
10
123
37
333
1.15
0.26
3.8
2.7
—
—
—
0
0
5
38
1.33
0.23
1.2
1.6
—
—
—
0
0
7
91
0.76
0.23
1.0
1.1
—
—
—
0
0
5
39
1.29
0.23
2.0
1.7
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
0.84
—
0
11
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
12
0.00
0.21
0.0
1.5
—
16527.71
—
0
7
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
125.57
—
0
7
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
98
1009
0.89
0.18
3.0
3.2
5.44
5.60
mmol/l
1.04
89
950
8
68
1.19
0.17
1.9
4.2
—
—
—
0
0
8
70
1.15
0.16
1.3
1.4
—
—
—
0
0
9
80
1.13
0.15
1.2
1.4
—
—
—
0
0
22
200
1.12
0.13
1.9
2.2
—
—
—
0
0
11
96
1.16
0.10
2.5
1.4
258.27
316.72
mu/l
0.69
11
82
10
114
0.87
0.10
1.0
1.5
—
—
—
0
0
10
114
0.87
0.10
1.3
1.4
—
—
—
0
0
6
53
1.14
0.09
4.3
3.1
—
—
—
0
0
13
117
1.12
0.08
1.3
1.2
—
—
—
0
0
5
61
0.81
0.08
1.4
1.2
—
—
—
0
0
7
66
1.06
0.08
1.3
1.1
—
—
—
0
0
7
83
0.83
0.07
2.0
7.3
1.02
1.00
mmol/l
—
7
75
13
118
1.11
0.07
1.3
1.1
—
—
—
0
0
9
87
1.04
0.07
1.2
1.4
—
—
—
0
0
9
87
1.04
0.07
1.2
1.4
—
—
—
0
0
9
87
1.04
0.07
1.2
1.4
—
—
—
0
0
48
464
1.05
0.07
1.9
1.7
—
—
—
0
0
9
88
1.02
0.07
1.2
1.4
—
—
—
0
0
37
355
1.06
0.07
1.5
1.8
—
—
—
0
0
10
110
0.90
0.05
1.2
1.4
—
—
—
0
0
10
110
0.90
0.05
1.2
1.4
—
—
—
0
0
31
298
1.05
0.05
1.3
1.3
0.46
1.31
u/ml
—
5
81
28
276
1.02
0.00
4.5
3.3
0.00
0.00
estimate
0.00
15
116
18
181
0.99
0.00
2.3
3.4
—
—
—
0
0
63
632
0.99
0.00
2.3
2.5
—
—
—
0
0
11
113
0.97
0.00
1.3
1.5
—
—
—
0
0
90
905
0.98
0.00
3.1
4.1
36.25
37.38
mmol/mol
0.77
81
869
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.2
—
1.29
—
0
5
0
5
0.00
0.00
0.0
1.6
—
—
—
0
0
0
5
0.00
0.00
0.0
6.0
—
7.45
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
4.0
—
20.84
—
0
9
0
5
0.00
0.00
0.0
1.0
—
6.00
—
0
5
0
5
0.00
0.00
0.0
1.8
—
8.28
—
0
5
0
5
0.00
0.00
0.0
1.0
—
10.46
—
0
5
0
9
0.00
0.00
0.0
2.6
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
2.4
—
0.91
—
0
5
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
454.80
—
0
5
9
90
1.00
0.00
2.3
2.8
0.79
1.68
ug/l
—
9
82
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
0.00
0.0
1.5
—
—
—
0
0
6
65
0.92
0.00
1.8
2.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
3.0
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
108.91
—
0
7
6
66
0.90
0.00
1.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
33.50
—
0
8
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
6
61
0.98
0.00
2.3
2.0
14.48
10.61
nmol/l
—
6
56
6
60
1.00
0.00
1.7
1.8
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: MSMED_PEGINTERFERONBETA1A – Use of peginterferon beta-1a

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).